Fig. 2From: Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysisOne-way sensitivity analysis tornado charts. IPSS International prostate symptom score FT Fexapotide triflutate, 5-ARI 5-α-Reductase inhibitorsBack to article page